Veru (NASDAQ:VERU – Get Rating) will release its earnings data before the market opens on Thursday, February 9th. Analysts expect Veru to post earnings of ($0.38) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Veru (NASDAQ:VERU – Get Rating) last posted its quarterly earnings data on Monday, December 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.22). The firm had revenue of $2.59 million for the quarter, compared to analysts' expectations of $11.51 million. Veru had a negative net margin of 212.88% and a negative return on equity of 69.57%. On average, analysts expect Veru to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Veru Stock Up 2.4 %

VERU opened at $5.90 on Thursday. The firm has a market capitalization of $475.66 million, a P/E ratio of -5.62 and a beta of -0.27. The firm's 50 day moving average is $5.57 and its 200-day moving average is $10.26. Veru has a 52-week low of $4.34 and a 52-week high of $24.55.

Institutional Trading of Veru

Analyst Ratings Changes

Separately, HC Wainwright dropped their price objective on shares of Veru from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, December 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $33.50.

About Veru

(Get Rating)

Veru, Inc is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.

Featured Stories

• Get a free copy of the StockNews.com research report on Veru (VERU)
• Bed Bath & Beyond Is Circling the Drain
• Allegro Microsystems Is A Well-Positioned Semiconductor Stock
• Scotts Miracle-Gro Hits Bottom, Reversal In Play
• Altria is a Great Recession Stock, Long-Term Outlook Uncertain
• Novavax Shares Jumped in January While Others Slipped

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.